• 
• 
• 
• 

FDA News and Drug Updates

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

FDA Grants Approval to Avapritinib for Patients with GIST

FDA News

Side-Effects Management

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

Wayne Kuznar

Suboptimal Dosing of Filgrastim Is Acceptable for Treatment of Chemotherapy-Induced Neutropenia

Audrey Andrews

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy

Phoebe Starr

View All Side-Effects Management Articles

Immunotherapy

FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer

CAR T-Cell Therapy Targeting Solid Tumors

Chase Doyle

CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma

Wayne Kuznar

Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy

Wayne Kuznar

CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring

Wayne Kuznar

View All Immunotherapy Articles

Conference Correspondent

Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain

Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation

Graft-versus-Host Disease: Breakthroughs on the Horizon

Basket Clinical Trials: A New Era in Cancer Treatment

Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation

Chemotherapy Treatment Considerations in Special Patient Populations

Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma

View All Conference Correspondent Articles

Most Popular Articles

Resistance to Acalabrutinib in Chronic Lymphocytic Leukemia Is Mediated Predominantly by BTK Mutations

Conference Correspondent  - ASH 2019 Post Wrap-Up

Triplet Therapy with Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Conference Correspondent  - ASH 2019 Post Wrap-Up

Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Conference Correspondent  - ASH 2019 Post Wrap-Up

CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak

Web Exclusives - Health Policy, In the News

Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial

Conference Correspondent  - ASH 2019 Post Wrap-Up